Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the drug's first full quarter on the market. A mere year ago, Madrigal had no ...

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

The president-elect has said he’ll let Robert F. Kennedy Jr. “go wild” on healthcare, while many expect a leadership change ...

Let's consider two examples: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA). Here's why these biotechs are ...

Brokers continue to weigh in. The post Are CSL shares a buy after the biotech's FY25 forecasts? appeared first on The Motley ...

Each year, we dive into the world of biotech closures and layoffs, tracking the industry’s pulse as companies navigate | This ...

The Pharma & Biotech market had a relatively muted month. There were a number of companies that experienced strong share ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

We recently compiled a list of the 10 AI News and Ratings Investors Should Not Miss. In this article, we are going to take a ...

This story was adapted from Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get ...

With climbing biotech M&A and IPO activity following the post-pandemic slump, experts offer insights on maximizing value and ...

Glassdoor, Payscale, or more specifically BioPharmGuy (to look through a large variety of job offers similar to yours) are ...